|
Sep 21
|
Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases
|
|
Sep 8
|
Why Is Cancer Diagnostic Focused Biocept Stock Trading Higher Today?
|
|
Sep 8
|
EXCLUSIVE: Cancer Firm Plus Therapeutics Licenses Diagnostic Assay To Detect Central Nervous System Cancers
|
|
Sep 8
|
Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics
|
|
Sep 5
|
Biocept to Participate in the H.C. Wainwright Global Investment Conference
|
|
May 25
|
Biocept Announces Pricing of $5.0 Million Underwritten Public Offering
|